Program
obinutuzumab
Also written as “Obinutuzumab”, “Obinutuzumab, naptumomab estafenatox and durvalumab” and “obinutuzumab (RO5072759)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lupus Nephritis · Lupus Erythematosus, Systemic, led by 2 companies.
Drug pageObinutuzumab: every studyAll 172 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 325 open or running | phase 4since Jan 24, 2019 | Aug 16, 2007 | Dec 28, 2026phase 2 · NCT04077723 |
| AbbVieits history only | 32 open or running | phase 3since May 20, 2024 | May 19, 2021 | Nov 2026phase 2 · NCT04895436 |
Also a collaborator on its studies: AstraZeneca and Roche Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Aug 16, 2007.
- Nov 3, 2015Phase 2 study in RecurrenceHoffmann-La Roche · NCT02600897 · 114 enrolled · United States, Spain, United Kingdom
- Dec 1, 2015Phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT02624986 · 25 enrolled · United States, Australia, Germany and more
- Jan 24, 2019Phase 4 study in Advanced Follicular LymphomaHoffmann-La Roche · NCT03817853 · 114 enrolled · United States, Brazil, Germany and more
- Mar 6, 2019Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT03866239 · 47 enrolled · United States, Denmark, France and more
- Aug 9, 2019Phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT04077723 · 498 enrolled · United States, Australia, Belgium and more
- Jan 7, 2020Phase 3 study in Lupus NephritisHoffmann-La Roche · NCT04221477 · 271 enrolled · United States, Argentina, Brazil and more
- Feb 25, 2020Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellHoffmann-La Roche · NCT04285567 · 166 enrolled · United States, Australia, France and more
- Oct 27, 2020Phase 3 study in Primary Membranous NephropathyHoffmann-La Roche · NCT04629248 · 142 enrolled · United States, Argentina, Brazil and more
- May 19, 2021AbbVie’s first study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNew to AbbVieAbbVie · NCT04895436 · 75 planned · United States, Australia, Austria and more
- Jul 7, 2021Phase 3 study in Lupus Erythematosus, SystemicHoffmann-La Roche · NCT04963296 · 303 enrolled · United States, Argentina, Brazil and more
- Sep 1, 2021Phase 2 study in Lupus NephritisHoffmann-La Roche · NCT05039619 · 40 planned · United States, Brazil, Canada and more
- Oct 25, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT05105841 · 20 enrolled · Japan
- Nov 4, 2022Phase 3 study in Nephrotic SyndromeHoffmann-La Roche · NCT05627557 · 85 enrolled · United States, Belgium, Brazil and more
- May 20, 2024Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT06428019 · 170 planned · United States, Australia, France and more
- Jul 19, 2026Named obinutuzumabINNProposed as its International Nonproprietary Name in WHO's List 135
Ahead
- Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT04895436
- Dec 28, 2026Primary completion: phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT04077723
- Mar 2028Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT06428019
- Jun 15, 2028Primary completion: phase 2 study in Lupus NephritisHoffmann-La Roche · NCT05039619
TargetBeta
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06428019Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 3 | Recruiting | AbbVie | Mar 2028 | 170 |
| NCT05627557Nephrotic Syndrome · United States, Belgium, Brazil and more | 3 | Completed | Hoffmann-La Roche | Sep 4, 2025 | 85 |
| NCT05105841Leukemia, Lymphocytic, Chronic, B-Cell · Japan | 2 | Completed | AbbVie | Oct 9, 2025 | 20 |
| NCT05039619Lupus Nephritis · United States, Brazil, Canada and more | 2 | Recruiting | Hoffmann-La Roche | Jun 15, 2028 | 40 |
| NCT04963296Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Sep 15, 2025 | 303 |
| NCT04895436Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 2 | Recruiting | AbbVie | Nov 2026 | 75 |
| NCT04629248Primary Membranous Nephropathy · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Dec 22, 2025 | 142 |
| NCT04285567Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 3 | Completed | Hoffmann-La Roche | Mar 19, 2024 | 166 |
| NCT04221477Lupus Nephritis · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Aug 15, 2024 | 271 |
| NCT04077723Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more | 2 | Active, not recruiting | Hoffmann-La Roche | Dec 28, 2026 | 498 |
| NCT03866239Colorectal Neoplasms · United States, Denmark, France and more | 1 | Terminated | Hoffmann-La Roche | Mar 13, 2024 | 47 |
| NCT03817853Advanced Follicular Lymphoma · United States, Brazil, Germany and more | 4 | Completed | Hoffmann-La Roche | Aug 4, 2020 | 114 |
| NCT02624986Lymphoma, Non-Hodgkin · United States, Australia, Germany and more | 2 | Terminated | Hoffmann-La Roche | May 20, 2019 | 25 |
| NCT02600897Recurrence · United States, Spain, United Kingdom | 2 | Completed | Hoffmann-La Roche | Dec 15, 2021 | 114 |
| NCT02586051Kidney Failure, Chronic · United States | 1 | Completed | Hoffmann-La Roche | Nov 26, 2018 | 24 |
| NCT02550652Lupus Nephritis · United States, Argentina, Brazil and more | 2 | Completed | Hoffmann-La Roche | Jan 15, 2019 | 126 |
| NCT02320487Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Hoffmann-La Roche | Nov 7, 2016 | 102 |
| NCT02071225Leukemia, Lymphocytic, Chronic, B-Cell · Spain | 2 | Completed | Hoffmann-La Roche | Nov 19, 2018 | 72 |
| NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more | 2 | Completed | Hoffmann-La Roche | Jun 28, 2017 | 267 |
| NCT02053610Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Aug 31, 2013 | 787 |
| NCT01998880Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Aug 1, 2012 | 787 |
| NCT01905943Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Belgium, Bosnia and Herzegovina and more | 3 | Completed | Hoffmann-La Roche | Dec 29, 2016 | 979 |
| NCT01868893Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Hoffmann-La Roche | Jan 2014 | 20 |
| NCT01691898Lymphoma, Follicular · United States, Canada, France and more | 2 | Completed | Hoffmann-La Roche | Mar 8, 2017 | 231 |
| NCT01685892Leukemia, Lymphocytic, Chronic, B-Cell · United States, United Kingdom | 1 | Completed | Hoffmann-La Roche | May 21, 2018 | 82 |
| NCT01680991Leukemia, Lymphoid · China | 1 | Completed | Hoffmann-La Roche | Dec 2014 | 48 |
| NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany | 1 | Completed | Hoffmann-La Roche | Aug 17, 2018 | 84 |
| NCT01414855Lymphoma, B-Cell · United States | 2 | Completed | Hoffmann-La Roche | Dec 31, 2013 | 100 |
| NCT01414205Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Hoffmann-La Roche | Mar 31, 2013 | 80 |
| NCT01332968Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Feb 1, 2016 | 1,401 |
| NCT01287741Lymphoma, Large B-Cell, Diffuse · United States, Argentina, Australia and more | 3 | Terminated | Hoffmann-La Roche | Apr 29, 2016 | 1,418 |
| NCT01059630Lymphoma, Non-Hodgkin · United States, Austria, Belgium and more | 3 | Completed | Hoffmann-La Roche | Sep 30, 2014 | 413 |
| NCT01010061Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Jul 1, 2012 | 787 |
| NCT00576758Lymphoma, Non-Hodgkin · United States, Argentina, Austria and more | 2 | Completed | Hoffmann-La Roche | Sep 2011 | 175 |
| NCT00517530Lymphoma · France, Germany | 2 | Completed | Hoffmann-La Roche | Nov 2013 | 134 |
How it is read
Names in the registry
- “Obinutuzumab”, 35 entries
- “obinutuzumab”, 5 entries
- “Obinutuzumab, naptumomab estafenatox and durvalumab”, 1 entry
- “obinutuzumab (RO5072759)”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 18 studies
- Lymphoma, Non-Hodgkin, 6 studies
- Lymphoma, Follicular, 4 studies
- Lupus Nephritis, 3 studies
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.